Research Funding Disparity
The economic argument for increased ME/CFS research funding is not that the disease is underfunded in absolute terms — it is that it is underfunded relative to its burden, in a pattern that distinguishes it from every other chronic disease of comparable severity.
Mirin et al. (2020) compared ME/CFS disease burden (IOM 2015 USD 17–24B estimate, plus DALY-based burden metrics) against NIH research funding (~USD 15M/year) and found a burden-to-funding ratio of approximately 1,000:1 — meaning the disease generates roughly USD 1,000 in economic cost for every USD 1 of NIH research funding (Mirin, Dimmock, and Jason 2020). By comparison, multiple sclerosis (annual cost USD 39,000–68,000/patient, comparable per-patient to ME/CFS) received ~USD 115M/year in NIH funding — a burden:funding ratio of ~30:1 (Simoens 2022). Rheumatoid arthritis (annual cost USD 12,000–21,000/patient) received ~USD 86M/year — ratio ~32:1 (Hsieh et al. 2020). The three-order-of-magnitude gap between ME/CFS and comparably burdensome diseases is the strongest single piece of quantitative evidence for research neglect. (Certainty: 0.65 — Mirin 2020 burden side relies on IOM 2015 modeled estimate; funding figures are public NIH data and verifiable; cross-disease comparators are systematic reviews. The ratio’s magnitude depends on the burden estimate — if IOM overestimated burden by 2x, the ratio is still ~500:1. The qualitative conclusion — ME/CFS is severely underfunded relative to burden — is robust to plausible variation in the burden estimate.)
Consequence: The burden:funding ratio is the chapter’s most politically actionable finding. For an NIH program officer, a congressional staffer, or a research charity allocating funds, the phrase 1,000:1 cost:funding ratio is a single number that captures the structural neglect. The cross-disease comparators (MS, RA) are critical — they establish that the disparity is not explained by inherent difficulties in studying ME/CFS (MS and RA are also complex, chronic, immune-mediated diseases with no cure) but by a systematic underinvestment that predates and is independent of any scientific challenge. Severity applicability: research funding affects all severity levels, but severe/very severe patients — who have the least capacity to participate in advocacy — are the most affected by funding scarcity, because they have the greatest need for treatment discovery and the least ability to travel to the few existing research centers.
The burden:funding ratio is a descriptive comparison, not a causal model. It shows disparity but does not answer the policy question: if ME/CFS research funding increased to parity with MS (~USD 115M), what return would that generate? A formal ROI analysis would require: (1) modeling the probability that increased funding yields a disease-modifying treatment within N years, (2) estimating what fraction of the USD 17–24B annual burden such a treatment would eliminate, and (3) discounting future benefits to present value. No such analysis exists for ME/CFS. The Cochrane 2021 systematic review confirmed that zero cost-effectiveness studies exist for any ME/CFS intervention — including research funding itself as an intervention (Cochrane et al. 2021).
Consequence: The burden:funding ratio is persuasive but not probative for a specific funding target. It tells you the present state is unjustified; it does not tell you what funding level would be optimal. In policy contexts, this distinction matters — a cost-effectiveness analyst will ask “what is the marginal return on the next 10 million dollars?” and the current literature cannot answer. This limitation is not a weakness of the case for increased funding; it is a consequence of the same underfunding that the case critiques. (Certainty: 0.75 — confirmed by Cochrane 2021 systematic review (Cochrane et al. 2021); absence of evidence for ROI of ME/CFS research funding is a documented finding from systematic search, not an assumption.) Severity applicability: the ROI gap affects evidence-based funding advocacy across all severity levels.